pomalidomide (pomalyst) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Pomalidomide is a derivative of thalidomide marketed by Celgene, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model.   NCATS

Chemistry

  • SMILES: NC1=CC=CC2=C1C(=O)N(C3CCC(=O)NC3=O)C2=O
  • InChIKey: UVSMNLNDYGZFPF-UHFFFAOYSA-N
  • Mol. Mass: 273.2441
  • ALogP: -0.33
  • ChEMBL Molecule:
    pomalidomide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$387.6500

United States

$568.9248 - $800.7579
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

actimid | cc4047 | cc 4047 | cc-4047 | imid3 | imid-3 | imid3 cpd | imnovid | pomalidomide | pomalyst

Organizations (155)

Research & Development (149)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (50)

Approved Indications (1)


 

Multiple Myeloma

Experimental Indications - Clinical Trial Phases 1-4 (50)


 

Amyloid (Phase 2)

Amyloidosis (Phase 2)

Anemia, Sickle Cell (Phase 1)

Burkitt Lymphoma (Phase 1)

Carcinoma, Small Cell (Phase 1/Phase 2)

Central Nervous System Neoplasms (Phase 2)

Chromosome Disorders (Phase 2)

Endoscopy (Phase 2)

Genetic Diseases, Inborn (Phase 2)

Glioma (Phase 1)

Graft vs Host Disease (Phase 2)

Healthy Volunteers (Phase 1)

HIV (Phase 2)

Hodgkin Disease (Phase 1)

Immunoglobulin Light-chain Amyloidosis (Phase 2)

Immunoglobulin Light Chains (Phase 1)

Intraocular Lymphoma (Phase 1)

Kidney Failure, Chronic (Phase 1)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Plasma Cell (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Lymphoma (Phase 1/Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, Primary Effusion (Phase 1/Phase 2)

Medulloblastoma (Phase 2)

Multiple Myeloma ()

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 1/Phase 2)

Neurofibromatosis 1 (Phase 1)

Pancreatic Neoplasms (Phase 1/Phase 2)

Pharmacology, Clinical (Phase 1)

Plasmacytoma (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 3)

Prostatic Neoplasms (Phase 2)

Pulmonary Fibrosis (Phase 2)

Recurrence (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Kaposi (Phase 2)

Scleroderma, Systemic (Phase 2)

Squamous Intraepithelial Lesions (Phase 2)

Telangiectasia, Hereditary Hemorrhagic (Phase 2)

Therapeutic Equivalency (Phase 1)

Thrombocytosis (Phase 2)

Vascular Diseases (Phase 1)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 213
  • # of Trial Organizations: 149

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue